CSL Limited Annual Report 2022/23 23 CSL’s 2030 Strategy CSL operates with a long-termmindset. Over time, we have served patients with life-saving therapies and effective vaccines. We have achieved consistent top-line growth and strong margins, which helps fuel further growth by allowing us to re-invest in our own businesses. CSL is committed to the 2030 Strategy which includes Focus in core therapeutic areas, Innovation, Efficiency & Reliable Supply, Sustainable Growth, and Digital Transformation, with people at the centre of our strategy. We believe this is the best path, given our capabilities in an increasingly challenging and competitive world. The core elements of the 2030 Strategy are represented below. CSL People & Culture Patients & Public Health • Immunology • Haematology • Cardiovascular & Metabolic • Respiratory • Transplant • Vaccines • Nephrology & Iron Therapy Efficiency & Focus Innovation Sustainable Growth Digital Transformation Reliable Supply • Products • Delivery • Services • Technology • Yield • Technology • Operational Excellence • Capital Project Execution • Partnerships • Plasma • Recombinants • Cell & Gene Therapy • Preventative Vaccines • Iron Therapy • Business Model • Connected Healthcare • New Capabilities CSL’s long-term priorities are focused on delivering sustainable, profitable growth. This will allow CSL to continue to provide a reliable supply of our life-saving therapies and to fund innovation that improves the health of patients and the public. We are leaders in protein therapies, influenza vaccines and the treatment of iron deficiency. For CSL Behring, our immunoglobulin franchise is growing strongly, driven by record levels of plasma collections. CSL Seqirus is delivering strong sales growth driven by differentiated products and has future growth potential with next-generation mRNA vaccine technology that is in late-stage development with our partner Arcturus Therapeutics. CSL Vifor provides new opportunities to grow the iron deficiency treatment franchise and in nephrology where there is significant unmet need to drive new indications, expand into new geographies and improve access. CSL provides life-saving products to patients in more than 40 countries and employs around 32,000 people globally. We have an extensive network of manufacturing sites across Australia, the United States, Europe and China. In addition, we look beyond our walls to partner with leading organisations across the value chain to support manufacturing, innovation, technology and other areas of our business. Delivering R&D CSL remains committed to investing in targeted and disruptive research and development (R&D) innovation to better meet the needs of patients and public health. This commitment is evidenced by the continued investment in R&D, surpassing US$1 billion annually in recent years, and the dedicated work of over 2,000 R&D employees across 10 countries who collaborate in integrated teams. CSL’s R&D organisation has made significant progress in key clinical programs spanning our four strategic scientific platforms and six therapeutic areas. Our R&D portfolio includes promising projects such as garadacimab, our anti-FXIIa monoclonal antibody for the potential long-term prophylactic treatment of patients with hereditary angioedema (HAE), CSL112, which aims to reduce the risk of recurrent cardiovascular events during the 90-day high-risk period following a heart attack, alpha-1 antitrypsin (AAT; ZEMAIRA®) for the prevention and treatment of acute graft-versus-host disease (GvHD), KCENTRA® for improving survival in trauma patients experiencing life-threatening bleeding, clazakizumab for the treatment of patients with end stage kidney disease and for patients who have received a kidney transplant, and next-generation vaccine technologies like sa-mRNA and aQIVc to safeguard public health. Moreover, our early-stage pipeline consists of other promising projects where CSL’s R&D team strives to challenge the status quo and explore improved options for people and patients.
RkJQdWJsaXNoZXIy MjE2NDg3